Equities

StageZero Life Sciences Ltd

StageZero Life Sciences Ltd

Actions
  • Price (USD)0.08
  • Today's Change0.00 / 0.00%
  • Shares traded15.00k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 14:45 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year StageZero Life Sciences Ltd's revenues fell -25.12% from 5.07m to 3.80m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 7.48m to a larger loss of 11.42m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in USDView more

In 2022, cash reserves at StageZero Life Sciences Ltd fell by 1.71m. Cash Flow from Financing totalled 1.83m or 48.29% of revenues. In addition the company used 3.53m for operations while cash from investing was breakeven.
Cash flow per share--
Price/Cash flow per share--
Book value per share-0.1119
Tangible book value per share-0.1119
More ▼

Balance sheet in USDView more

StageZero Life Sciences Ltd uses little or no debt in its capital structure.
Current ratio0.02
Quick ratio0.0176
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.